| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | 10% Owner | Director
5 companies
Leslie W. Kreis last filed a Form 4 in June 2025, as Director, 10% Owner at INAB. The filings on record cover 5 companies. Leslie W. Kreis's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Leslie W. Kreis a below-average insider score of 45/100, based on 28 past trades. Over a 12-month horizon, 32.1% of those trades were profitable, with an average 12-month return of -16.7%.
At the last filing, the largest reported position was 570,724 shares of INAB. Net of sales, the INAB filings show accumulation of 1,974,899 shares.
Leslie W. Kreis has 32 Form 4 filings on record from June 2020 to June 2025, across 5 companies: Director, 10% Owner at Actuate Therapeutics (ACTU), 2024–2025; Director, 10% Owner at Cognition Therapeutics (CGTX), 2022–2025; 10% Owner at Lantern Pharma (LTRN), 2020–2025, and 2 more.
The 182 reported transactions were 68 open-market sales, 46 conversions, 43 open-market purchases and 10 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 11 purchases worth about $13.2M and 10 sales worth about $3.9M.
The largest open-market purchase was 500,000 shares of ACTU at an average $8.00 on August 14, 2024, about $4.0M. Twelve months later ACTU was down 10%.
The largest open-market sale was 350,000 shares of LTRN at an average $4.40 on November 8, 2022, about $1.5M. Twelve months later LTRN was down 36%.
None of the 8 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
Shares as reported in the last Form 4 for each company; the most recent is from June 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 27, 2025 | ACTU Actuate Therapeutics, Inc. | Director, 10% Owner | Buy | 71,428 | $7.00 | $499,996.00 | +57.1% | +11.6% | -71.8% | |
| Jun 13, 2025 | LTRN Lantern Pharma Inc. | 10% Owner | Sell | 40,000 | $3.09 | $123,600.00 | -25.9% | +28.9% | +27.2% | |
| Jun 12, 2025 | LTRN Lantern Pharma Inc. | 10% Owner | Sell | 61,613 | $3.38 | $208,271.26 | -34.2% | +22.6% | +20.1% | |
| May 29, 2025 | LTRN Lantern Pharma Inc. | 10% Owner | Sell | 56,237 | $2.99 | $168,418.85 | -31.0% | +29.4% | +14.7% | |
| Aug 14, 2024 | ACTU Actuate Therapeutics, Inc. | 10% Owner | Sell | 24,999 | $9.00 | $224,991.00 | -16.0% | -1.4% | -10.2% | |
| Aug 14, 2024 | ACTU Actuate Therapeutics, Inc. | 10% Owner | Buy | 500,000 | $8.00 | $4,000,000.00 | -133.3% | -1.4% | -10.2% | |
| May 24, 2024 | LTRN Lantern Pharma Inc. | 10% Owner | Sell | 30,000 | $6.30 | $189,100.00 | -18.6% | -32.7% | -47.5% | |
| Feb 29, 2024 | LTRN Lantern Pharma Inc. | 10% Owner | Sell | 144,000 | $4.70 | $676,294.06 | -51.1% | +24.9% | -17.9% | |
| Jan 17, 2024 | LTRN Lantern Pharma Inc. | 10% Owner | Sell | 58,889 | $4.20 | $247,333.80 | -25.9% | +60.9% | -3.5% | |
| Nov 29, 2023 | LTRN Lantern Pharma Inc. | 10% Owner | Sell | 145,348 | $3.44 | $499,997.12 | -28.1% | +15.1% | -17.9% |